Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
# | Type | Title | Authors | Category | Keywords |
---|---|---|---|---|---|
780 | Poster Presentation | ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity | Ons Harrabi, BA; Amy Chen; Emma R. Sangalang; Danielle Fontaine; Min Li, PhD; Jaume Pons, PhD; Hong I. Wan, PhD; Janet Sim, PhD; Tracy C. Kuo, PhD | Immuno-conjugates and chimeric molecules | Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR |
781 | Poster Presentation | GT-001 - anti-Lewis Y antibody with superior fine-specificity and reduced off-target binding | Anika Jaekel; Patrik Kehler; Timo Lischke; Lisa Weiß; Christoph Goletz; Evelyn Hartung; Anke Flechner; Sven Bahrke; Johanna Gellert; Antje Danielczyk | Immuno-conjugates and chimeric molecules | Antibody;Solid tumors;Targeted therapy;Tumor antigens |
782 | Poster Presentation | PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models | Justin A. Kenkel, PhD; Rishali Gadkari; Karla A. Henning, PhD; Romas Kudirka; William G. Mallet; Po Y. Ho; Ganapathy Sarma; Steven J. Chapin, PhD; Liz Bogaert; Jennifer E. Melrose; Matthew N. Zhou; Suprit Deol; Cindy L. Kreder; Yuyi Shen; Puneet Anand; Arthur Lee; Hai Li; Shelley E. Ackerman; Brian S. Safina; David Dornan, PhD; Michael N. Alonso, PhD; Marcin Kowanetz, Ph.D. | Immuno-conjugates and chimeric molecules | Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Targeted therapy;TLR;Tumor antigens |
783 | Poster Presentation | SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors | Byron Kwan, PhD; Megan Ramirez; Steven Jin; Changpu Yu; Serena W. Wo; Priyanka Gupta; Sean Allred; Jessica K. Simmons; Kelly M. Hensley; Christina Zuch de Zafra; Haley Neff-LaFord; Shawna Hengel; Andres Forero-Torres, MD; Heather Van Epps | Immuno-conjugates and chimeric molecules | Antibody;Chemotherapy;Solid tumors;Targeted therapy |
784 | Poster Presentation | BDC-2034: Discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors | William G. Mallet; Rishali Gadkari; Cecelia I. Pearson; Laughing Bear Torrez Dulgeroff; Angela Luo; Andrew Luo; Jennifer E. Melrose; Jess L. Nolin; Arthur Lee; Matthew N. Zhou; Puneet Anand; Ganapathy Sarma; Karla A. Henning, PhD; Lisa K. Blum; Steven J. Chapin, PhD; Liz Bogaert; Shelley E. Ackerman; Romas Kudirka; Yuyi Shen; Amreen Husain; Edith A. Perez; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Brian S. Safina; David Dornan, PhD | Immuno-conjugates and chimeric molecules | Antibody;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens |
785 | Poster Presentation | STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells | Phonphimon Wongthida, PhD; Kalli C. Catcott, PhD; Kelly Lancaster; Keith Bentley, PhD; Anouk Dirksen, PhD; Bingfan Du; Timothy Eitas, PhD; Eugene W. Kelleher; Naniye Malli, PhD; Rebecca Mosher, MD; Marina Protopopova, PhD; Pamela Shaw; Cheri Stevenson; Joshua D. Thomas, PhD; Alex Uttard; Jeremy Duvall, PhD; Dorin Toader, PhD; Marc Damelin, PhD; Raghida A. Bukhalid, PhD; Timothy B. Lowinger, PhD | Immuno-conjugates and chimeric molecules | Antibody;Chemokine;Cytokine;Monocyte/Macrophage;T cell;Targeted therapy;Tumor microenvironment |
786 | Poster Presentation | Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data | Gaurav Bajaj; Fereshteh Nazari; Marc Presler; Craig Thalhauser; Ulf Forssmann; Maria Jure-Kunkel; Alexander Muik; Eleni Lagkadinou; Özlem Tureci; Ugur Sahin; Tahamtan Ahmadi; Manish Gupta | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;NK/NKT cell;Solid tumors;T cell |
787 | Poster Presentation | Natural Killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines | Katrina Bykova, PhD; Matthew S. Faber, PhD; Ke Liu, PhD; Noor Siddiqi; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Juan E. Diaz, PhD; Dong Hyun Nam, PhD; Kendra N. Avery, PhD; Jing Qi, PhD; Rumana Rashid, PhD; Rena Bahjat, PhD; John R. Desjarlais, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;NK/NKT cell;Solid tumors;T cell |
788 | Poster Presentation | A Novel T- Lymphocyte Binding Aptamer Assembled into a Bispecifc Compound for the Treatment of Solid Tumors | Irit Carmi Levy, PhD; Erez Lavi; Neta Zilony Hanin; Zohar Pode; Karin Mizrahi; Ronit Farhi; Anastasia Paz; Neria Reiss; Chen Shimoni; Vitaliy Buravenkov; Liron Levy-Efrati; Rotem Haimovich; Ohad Glaich; Itay Liron; Hadas Aharoni Zazrin; Ido Bachelet; Raanan Berger, MD; Guy Neev | Immuno-conjugates and chimeric molecules | Antigen presenting cells;Bispecifics;Solid tumors;T cell;TLR |
789 | Poster Presentation | Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule to enhance targeted tumor cytotoxicity | Fay Dufort, PhD; Christopher Leitheiser, PhD; Gemma Mudd, PhD; Julia Kristensson, .; Alexandra Rezvaya, MS; Elizabeth M. Repash, MSc; Eric Haines, PhD; Katie Gaynor, PhD; Sandra Uhlenbroich, PhD; Liudvikas Urbonas; Heather Allen; Helen Harrison; Liuhong Chen; Philip E. Brandish; Kevin McDonnell; Nicholas Keen | Immuno-conjugates and chimeric molecules | NK/NKT cell;Solid tumors |
790 | Poster Presentation | DSP502 — A Novel Approach For Targeting TIGIT And PD1 Pathways For Cancer Immunotherapy | Ayelet Chajut; Shirley Greenwald; Matthew C. Weber, PhD; Ami Tamir, PhD; Iris Pecker, PhD; Rinat Tabakman, PhD; Lucy Ganthous; Liat Tamir, PhD; Roy Kahn, PhD; Jasmine Avichzer; Alexandra Aronin; Elina Zorde-Khvalevsky; Amnon Peled, PhD; Michal Michal Elhalel Dranitzki, Dr.; Adam Foley-Comer, Dr.; Mark L. Tykocinski, Dr. | Immuno-conjugates and chimeric molecules | Bispecifics;Checkpoint blockade;Coinhibition;NK/NKT cell;Targeted therapy;Tumor microenvironment |
791 | Poster Presentation | Multi-specific Guidance and Navigation Control (GNC) T cell engagers convert PDL1 adaptive resistance to drug sensitivity | Jahan S. Khalili, Ph.D.; Mark Gilchrist; Sarah Rickli; Daphne Toglia; Yi Zhu | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;T cell;Tumor antigens;Tumor microenvironment |
792 | Poster Presentation | Creating an Immune-favorable Tumor Microenvironment by A Novel Anti-CD39/TGFβ-Trap Bispecific Antibody | Hongtao Lu, PhD; Dawei Sun, Ph.D.; Jun Sun; Yanan Geng; Jinhui Zhang, Ph.D.; Rui Gao, Ph.D.; Lei Li; Zhihao Wu, Ph.D; Lily Tang; Yangsheng Qiu, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment |
793 | Poster Presentation | Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms | Raymond J. Moniz, PhD; Ahmet Vakkasoglu; Zohra Merazga, MSc; Tina Daigneault; Steve N. Quayle, PhD; Natasha Girgis, Ph.D.; Ronald D. Seidel, PhD; John F. Ross, Ph.D.; Simon Low, MSc; Anish Suri, PhD | Immuno-conjugates and chimeric molecules | Bispecifics;Cytokine;Neoantigens;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine |
794 | Poster Presentation | Long-term anti-tumor preclinical efficacy of an optimized anti PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity | Aurore morello; Margaux Seite; justine durand; Geraldine Teppaz; Virginie Thepenier; caroline Mary; Isabelle Girault; Emmanuelle Wilhem; Nicolas Poirier | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
795 | Poster Presentation | APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors | Michelle H. Nelson, PhD; Ashly Lucas; Rebecca Gottschalk; Catherine McMahan; Jane Gross; Hilario Ramos | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;NK/NKT cell;T cell |
796 | Poster Presentation | ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors | Michelle H. Nelson, PhD; Anette Sundstedt; Yago Pico de Coaña, PhD; Ashly Lucas; Anneli Nilsson; Lill Ljung; Allison Chunyk; Lena Schultz; Catherine McMahan; Jane Gross; Sara Frizell, PhD; Hilario Ramos; Peter Ellmark, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy |
797 | Poster Presentation | A novel anti-PD-1/IL15 bi-functional antibody with robust anti-tumor activity in multiple solid tumors | DAN LU, MS; Tzu-Pei Chang, PhD; Zhanna Polonskaya; Stella Martomo, PhD; Xenia Luna; zhikai zhang; Stanley Ng; Jeegar Patel | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Checkpoint blockade;Cytokine;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs) |
798 | Poster Presentation | CDX-585, A bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways | Laura Vitale; Michael Murphy, Ph.D.; Collin Xia; Zeyu Peng; Thomas O'Neill; Ed Natoli; Jay Lillquist; Linda Crew; Anna Wasiuk, Ph.D.; Jeff Weidlick; Jenifer Widger; Laura Mills-Chen; Andrea Crocker; Colleen Patterson; James Boyer; April R. Baronas; Russell Hammond, Ph.D.; Hugh Davis; Mark Ma; Joel J. Goldstein, PhD; Lawrence J. Thomas, PhD; Diego Alvarado, Ph.D.; Henry Marsh, BS PhD; Tibor Keler, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;T cell;TLR |
799 | Poster Presentation | Neoantigen-cytokine-chemokine Multifunctional Natural Killer Cell Engager for Immunotherapy of Solid Tumors | Xue Yao, Master; Sandro Matosevic, PHD | Immuno-conjugates and chimeric molecules | Bispecifics;Chemokine;Cytokine;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment |
800 | Poster Presentation | Dual targeting of CTLA-4 and CD47 on Treg cells rejuvenates immunity against solid tumors | Anli Zhang, PhD; Zhenhua Ren, PhD; Kuo-fu Tseng; Xiajuan Liu; Huiyu Li, BS; Changzheng Lu; Yueqi Cai; John D. Minna, M.D.; Yang-Xin Fu, MD, PhD | Immuno-conjugates and chimeric molecules | Antibody;Bispecifics;Immune suppression;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;T cell;Targeted therapy |